Experience

Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Turning Point Therapeutics, Inc. of its common stock for up to an aggregate amount of $250 million…

Davis Polk advised the underwriters in connection with the SEC-registered offering by BioXcel Therapeutics, Inc. of 4,000,000 shares of its common stock. The common stock is listed on the…

Davis Polk advised the sole placing agent for the placement of 56,200,000 new shares and 36,800,000 existing shares in Innovent Biologics, Inc., for an aggregate consideration of…

Davis Polk advised the underwriters in connection with an initial public offering of 11,000,000 shares of common stock of Nurix Therapeutics, Inc. at $19 per share, for total gross proceeds…

Davis Polk advised the representatives of the underwriters in connection with the $511.5 million SEC-registered offering of 5,500,000 American Depositary Shares of BioNTech SE. In addition,…

Davis Polk advised the underwriters in connection with an initial public offering of 9,315,000 shares of common stock of Berkeley Lights, Inc. at $22.00 per share (which includes the…

Davis Polk advised the representatives of the several underwriters in connection with a $125 million SEC-registered common stock offering by Atreca, Inc. The common stock is listed on…

Davis Polk advised the sales agent in connection with an SEC-registered at-the-market offering by InflaRx N.V. of its shares of common stock for up to an aggregate amount of $50…

Davis Polk advised the representatives of the underwriters in connection with an initial public offering of Inventiva S.A.’s 7,478,261 American Depositary Shares. Aggregate gross…

Davis Polk advised Centogene N.V. on its $49 million follow-on public offering of 3,500,000 of its common shares, consisting of 2,000,000 common shares offered by Centogene and 1,500,000…